tbuckley/cabot-search huggingface dataset:
AB0408 Increase of body mass index in a tight controlled methotrexate-based strategy with prednisone in early rheumatoid arthritis (CAMERA-II): Is it a side-effect of the prednisone or better control of disease activity?
Authors: M.S. Jurgens, J.W. Jacobs, M.M. Geenen, E.R. Bossema, M.F. Bakker, J.W. Bijlsma, G.A. van Albada-Kuipers, J.C. Ehrlich, F.P. Lafeber, P.M. Welsing
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> In the Computer Assisted Management of Early RA trial-II (CAMERA-II),patients aged ≥18 years with early RA (disease duration &lt;1 year and no prior use of DMARDs) were included and randomized to an MTX-based tight control strategy with either 10 mg of Prednisone (MTX+pred) or placebo (MTX+plac)[1]. The MTX+predgroup had lower disease activity, disability and less erosive joint damage, compared to the MTX+plac group, but gained significantly more in weight than the MTX+plac group: mean 2.9 kg (standard deviation, SD 4.2) versus 1.3 kg (SD 5.3), p=0.03. <h3>Objectives</h3> To examine the association of glucocorticoids and disease activity with subsequent changes in body mass index (BMI). Furthermore the effect of BMI on disease activity was investigated. <h3>Methods</h3> Data from 224 patients of the CAMERA-II trial with monthly measurements of disease activity (DAS28) and BMI were used. Longitudinal regression (mixed model) analysis with BMI as dependent variable and DAS28 and treatment strategy as independent variables correcting for possible confounders (age, gender, rheumatoid factor, baseline BMI) was used. Separately, a longitudinal regression analysis with DAS28 as dependent variable and BMI and treatment strategy as independent variables, correcting for possible confounders was performed. To study the associations between disease activity and BMI several time lags between these variables were tested and the best fitting model was selected. To further focus on the longitudinal associations within patients an autoregressive model was used. <h3>Results</h3> There was no independent association of glucocorticoid therapy with changes in BMI. A decrease in DAS28 resulted in an increase in BMI 6 months later; also a rise in BMI was associated with a rise in DAS28 6 months later. <h3>Conclusions</h3> The higher BMI in the MTX+pred group seems (at least partly) attributable to a reduction of disease activity. A rise in BMI is associated with a rise in disease activity. <h3>References</h3> Bakker MF, Jacobs JWG, et al. Low-Dose Prednisone Inclusion in a Methotrexate-Based, Tight Control Strategy for Early Rheumatoid Arthritis. A Randomized Trial. Ann Intern Med 2012; 156: 329-39 <h3>Disclosure of Interest</h3> None Declared
P4-09-35: Co-Expression of Ki-67 Is Critical for Outcome of Cyclooxygenase-2 Positive Breast Cancer.
Authors: S Park, JS Koo, JS Lee, H Hwang, S Ko, SI Kim, B-W Park
Journal: Cancer Research (2011)

Abstract Background The purpose was to investigate the implications of cyclooxygenase-2 (COX-2) and Ki-67 expression on the progression and prognosis of breast cancer. Methods: COX-2 and Ki-67 levels were immunohistochemically determined using tissue microarrays of 1,028 breast tumors treated between November 1999 and August 2005. COX-2 and Ki-67 levels were compared by tumor progression and clinicopathological parameters were investigated in association with both markers status which was divided into 3 subgroups: COX-2(+)/Ki-67(+), COX-2(+)/Ki-67(−), COX-2(−)/Ki-67(any). Results: COX-2 expression was significantly higher in intraductal carcinoma and progressively decreased in small T1 lesions and then in T2-T4 tumors, but Ki-67 was significantly expressed at high levels in T2-T4 lesions than in intraductal or T1 carcinomas. COX-2 expression was positively associated with favorable parameters such as older age at diagnosis, smaller size, well-differentiation, hormone receptor-positivity, and was inversely associated with Ki-67 expression. Among 816 invasive tumors, COX-2 expression alone was not related to outcomes. In combination with Ki-67 expression, however, COX-2(+)/Ki-67(−) tumors were significantly associated with favorable characteristics including HER2−negativity and demonstrated favorable outcomes. COX-2(+)/Ki-67(+) tumors showed unfavorable factors and the worst outcomes. COX-2(−)/Ki-67(any) subgroup presented intermediate prognosis. Statistical significance of COX-2 combined with Ki-67 was maintained in Cox's models adjusting for clinicopathological parameters among not only whole population but also ER-positive subgroup. Conclusions: Our study suggests that COX-2 is expressed in early phase of breast cancer development and is associated with favorable prognostic markers. But co-expression of high Ki-67 proliferative index could indicate an aggressive phenotypic change in COX-2 positive breast cancer. The mechanisms should be further investigated. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P4-09-35.
Peroral endoscopic myotomy (POEM) for achalasia after Roux-en-Y gastric bypass
Authors: Dennis Yang, Peter Draganov
Journal: Endoscopy (2014)

Achalasia is a relatively rare esophageal motility disorder which has been reported to have an incidence of 1 % in the morbidly obese population [1] [2]. In line with the increase in number of severely obese individuals and concomitant rise in weight-loss procedures, post-bariatric surgery patients with symptomatic achalasia pose a surgical challenge. We present a patient with achalasia and Roux-en-Y gastric bypass (RYGB) successfully treated with peroral endoscopic myotomy (POEM).
AB1263 Higher prevalence of anti-citrullinated protein antibodies (ACPA) without impact on prognosis in patients with aggressive B-non-hodgkin lymphoma (DLCBL):
Authors: G. Assmann, K. Shihadeh, M.F. Ong, M. Ziepert, V. Poeschel, M. Pfreundschuh
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> The complex processes of citrullination presents an ubiquitous pathophysiological procedure during inflammation. However, anti-citrullinated protein antibodies (ACPA) are highly specific for the rheumatoid arthritis (RA). In order to a variety of several autoimmune phenomenons during the course of lymphoma diseases the occurrence of autoantibodies like rheumatoid factors (RF) and antinuclear autoantibodies (ANA) has been reported. <h3>Objectives</h3> Detecting the prevalence of anti-citrullinated protein antibodies (ACPA) in patients with DLCBL and its impact on prognosis including overall survival. <h3>Methods</h3> We conducted a case control study analyzing 395 sera of patients DLCBL and of 249 healthy controls (HC) to compare the frequency of ACPA-positivity using the χ2-tests for 2×2 tables (with fisher correction as required). In addition, DLCBL patients were stratified into gender, age, stage of lymphoma disease, ESR, LDH elevation, ECOG performance status, and overall survival (analyzed by Mann-Whitney-test and Kaplan-Meyer-curve, respectively). <h3>Results</h3> The A-CCP have been detected in the sera of 14 DLCBL patients (3.5%) more frequently than in the sera of HC (n=2, 0.8%, p=0.030). The subgroup analysis of female patients in both cohorts showed 4.4% ACPA positive DCBL patients and no HC (p=0.018). Data of DLCBL patients stratified into gender, age $&lt;&gt;$60y, stage of disease, performance status, ESR, LDH elevation, and overall survival (OS) show no differences between ACPA positive and negative patients (table). However, there was a trend towards better 6-year OS for ACPA positive cohort (66.79% versus 60.26%). <h3>Conclusions</h3> The patients with aggressive B-Non-Hodgkin lymphoma (DLCBL) showed more frequently anti-citrullinated protein antibodies (ACPA) compared to healthy controls. However, the ACPA could not been proved as a prognostic marker for DLCBL. <h3>Disclosure of Interest</h3> None Declared
Survey of Myeloblastoma With Ga-67 Scan in a Patient With Acute Leukemia
Authors: TERUHIKO TAKAYAMA, JUNICHI TAKI, SHIRO TSUJI, SEIGO KINUYA, TAKATOSH MICHIGISHI, NORIHISA TONAMI
Journal: Clinical Nuclear Medicine (1997)

A 60-year-old woman with acute myelogeneous was in remission after three courses of chemotherapy leukemia. She also had a proven and symptomatic myeloblastoma in the sacrum, which was localized with Ga-67. Bone scan showed no abnormality. New areas of Ga-67 uptake appeared in the regions of the mandibul, neck, mediastinum, and right lower extremity and an open biopsy of the mass in the right lower leg confirmed another myeloblastoma. Ga-67 scan was useful in localizing the unsuspected sites of myeloblastic infiltration, monitoring the response to therapy, and identifying concurrent inflammatory disease.
Abstract 5022: Immune biology drives cancer specific methylation profiles in blood
Authors: Devin C. Koestler, Carmen J. Marsit, Brock C. Christensen, William Accomando, Scott M. Langevin, Eugene A. Houseman, Heather H. Nelson, Margaret R. Karagas, John K. Wiencke, Karl T. Kelsey
Journal: Cancer Research (2012)

Abstract Blood leukocytes from patients with solid tumors exhibit complex and distinct cancer-associated patterns of DNA methylation. However, the biological mechanisms underlying these patterns remain poorly understood. Since epigenetic biomarkers offer significant clinical potential for cancer detection, we sought to address a mechanistic gap in recently published works, hypothesizing that this variation is in large part due to shifts in leukocyte populations. To discern differentially methylated regions (DMRs) among leukocyte subtypes, we assessed epigenome-wide DNA methylation in sorted, purified, healthy human peripheral blood leukocyte subtypes. Performing a targeted analysis of leukocyte DMRs from epigenome-wide blood methylation data in three independent case-control studies of different cancers revealed that leukocyte DMRs predict case status with a high degree of accuracy (area under the curve = 0.82, 0.83, and 0.67, forhead and neck squamous cell carcinoma (HNSCC), ovarian, and bladder cancer, respectively). These results demonstrate that blood-derived differences in DNA methylation patterns in patients with solid tumors are largely attributable to systematic differences in the DMRs that define specific, known leukocyte sub-populations, suggesting that the unique epigenetic signatures in blood from solid tumor patients arise as a result of immune responses represented by shifts in leukocyte populations. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 5022. doi:1538-7445.AM2012-5022
Extraosseous Metastases of Hepatocellular Carcinoma
Authors: NAOKO HAYASE, MITSUTAKA FUKUMOTO, DAISUKE YOSHIDA, SHINJI KARIYA, NAOKI AKAGI, ATSUSHI KUROHARA, NAOFUMI HISA, SHOJI YOSHIDA
Journal: Clinical Nuclear Medicine (1999)

Owing to recent advances in imaging technology and radiologic intervention, survival rates in patients with hepatocellular carcinoma have improved markedly. However, such prolonged survival has resulted in an increase in extrahepatic metastases. Tc-99m (Sn)-N-pyridoxyl-5-methyltryptophan (Tc-99m PMT), developed for hepatobiliary scintigraphy, has been used to visualize extrahepatic metastases, with most related reports limited to osseous metastases. The authors report two cases of hepatocellular cancer presenting as a hypopharyngeal metastasis and intraperitoneal dissemination along the tract of a fine-needle biopsy. Lesions undetectable on planar imaging could be visualized by Tc-99m PMT SPECT.
ANGINA CHARACTERISTICS AS PREDICTORS OF TRAJECTORIES OF QUALITY OF LIFE FOLLOWING ACUTE CORONARY SYNDROME IN THE TRANSITIONS, RISKS AND ACTIONS IN CORONARY EVENTS-CENTER FOR OUTCOMES RESEARCH AND EDUCATION COHORT
Authors: Lisa Nobel, Jennifer Tjia, Molly E. Waring, Jane Saczynski, Milena D. Anatchkova, Catarina Kiefe, Arlene Ash, Jeroan J. Allison
Journal: Journal of the American College of Cardiology (2016)
IMPACT OF THROMBOCYTOPENIA ON PROGNOSIS AFTER PERCUTANEOUS CORONARY INTERVENTION
Authors: Claire E. Raphael, Daniel Spoon, Malcolm Bell, Peter J. Psaltis, Stephen Kidd, Shu Xian Loh, Ryan Lennon, Charanjit Rihal, Mandeep Singh, Rajiv Gulati
Journal: Journal of the American College of Cardiology (2016)
Abstract 1943: Anticarcinogenic effect of curcumin by insulin-like growth factor-1 signaling inhibition
Authors: Hyoseon Kim, Eunjung Kim
Journal: Cancer Research (2011)

Abstract Curcumin (diferuloylmethane) is an active polyphenol natural product isolated from turmeric (the rhizome of the plant Curcuma longa Linn) and is traditionally used as a coloring agent and spice in food. Curcumin has also been shown to a powerful therapeutic agent against many human diseases including cancer. Insulin-like growth factor-1(IGF-1) signaling plays a critical role in regulation of cell survival, proliferation and growth. In this study, we investigated IGF-1 signaling inhibitory activity of curcumin and its mechanism in in vitro cell culture studies and in vivo tumor studies using BK5. IGF-1 transgenic mice. Serum starved HeLa cells were treated with curcumin of various concentrations and times and then stimulated with IGF-1(20 ng/ml) for 30 min. Akt(S473) and S6K(T389) phosphorylation was inhibited by 1 hr treatment of 40 and 30 μM curcumin, respectively. Moreover, curcumin treatment inhibited S6K phosphorylation even after 10 min treatment. Akt was not affected at this dosage and time of curcumin treatment. Curcumin also inhibited amino acids stimulated S6K phosphorylation whereas it activated Akt phosphorylation by negative feedback inhibition. This S6K phospholylation inhibitory activity of curcumin was comparable to that of rapamycin(20 nM) but the effect of curcumin appears to be transient. In our in vivo tumor study, supplementaion of curcumin to AIN-93G diet(0.02 % curcumin wt/wt) decreased mouse skin tumor multiplicity by 50 % as well as tumor size in BK5. IGF-1 transgenic mice. Curcumin supplementation also inhibited skin epithelial cell proliferation in 5-bromo-2-deoxyuridine(BrdU) incorporation experiment. Taken together, these data suggest that curcumin may exert its anticarcinogenic effect by directly inhibit IGF-1 stimulated mammalian target of rapamycin(mTOR) signaling. [This research was supported by Basic Science Research Program(C00308) and by SRC program(Center for Food &amp; Nutritional Genomics:2010-0001886) through the National Research Foundation of Korea(NRF) funded by the Ministry of Education, Science and Technology.] Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1943. doi:10.1158/1538-7445.AM2011-1943
THE EFFICACY OF PERCUTANEOUS TRANS-VENOUS MITRAL ANNULOPLASTY FOR THE TREATMENT OF FUNCTIONAL MITRAL REGURGITATION: PREDICTIVE VALUE OF ECHOCARDIOGRAPHIC PARAMETERS
Authors: Tomasz Siminiak, Piotr Kalmucki, Olga Jerzykowska, Artur Baszko, Rafal Dankowski, Andrzej Szyszka
Journal: Journal of the American College of Cardiology (2016)
Survival in Myeloblastic Leukemia of Adults
Authors: William Dameshek, Thomas F. Necheles, Harvey E. Finkel
Journal: New England Journal of Medicine (1966)

SURVIVAL in myeloblastic leukemia of adults has not appreciably changed since the advent of chemotherapy. As pointed out by Gunz et al.,1 the progress of the disease may be quite variable, but it usually follows a rapidly downhill course, with death ensuing within several weeks to months. A few patients, however, may live in apparent symbiosis with their disease for periods of up to several years. These cases, unfortunately, are uncommon. Recently, several reports have appeared suggesting that aggressive chemotherapy with combinations of agents may prolong life in this disease.2 3 4 To evaluate these studies in the light of our own . . .
COMPARATIVE EFFECTIVENESS OF HYBRID ABLATION VERSUS ENDOCARDIAL ABLATION ALONE IN PATIENTS WITH PERSISTENT ATRIAL FIBRILLATION: A RETROSPECTIVE ANALYSIS
Authors: Jasbir Sra, Jodi L. Zilinski, Indrajit Choudhuri, Lynn M. Erickson, Tadele W. Mengesha, David Krum, David C. Kress
Journal: Journal of the American College of Cardiology (2016)
Abstract 5357: Pediatric preclinical evaluation of the PARP inhibitor olaparib
Authors: Robin E. Norris, Peter C. Adamson, Elizabeth Fox
Journal: Cancer Research (2011)

Abstract Purpose: Olaparib (AZD2281) is an oral poly(ADP)-ribose polymerase (PARP) inhibitor in clinical development as a single agent and in combination with cytotoxic therapy in adults with solid malignancies. In BRCA-1 deficient tumors, olaparib concentrations of 30 nM result in significant PARP inhibition (Rottenberg, PNAS, 2008). Adult patients appear to tolerate olaparib doses associated with a Cmax of 10 µM (Fong, NEJM, 2009). We evaluated the interaction of olaparib with commonly used cytotoxic drugs in a panel of pediatric solid tumor cell lines. Methods: In vitro growth inhibition was assessed using the sulforhodamine B assay in pediatric solid tumor cell lines including: osteosarcoma (MG-63), neuroblastoma (NGP), Ewings sarcoma (RD-ES), medulloblastoma (Daoy), and rhabdomyosarcoma (RD). IC50's were determined following a 120 h exposure to vehicle, olaparib, cytotoxic agent (carboplatin, melphalan, irinotecan, doxorubicin, vincristine) or olaparib in combination with each cytotoxic agent. The combination index (CI) of Chou-Talalay was used to test for synergy of combinations. Results: As a single agent, olaparib was cytotoxic in all cell lines studied, with a median (range) IC50 of 1.7 (0.3-5.3) μM. The Ewings sarcoma cell line was the most sensitive line with a mean (SD) IC50 of 0.7 (0.3) μM. The combination of olaparib with melphalan or irinotecan was synergistic (CI &amp;lt; 1), while the addition of olaparib to doxorubicin or carboplatin appeared additive to synergistic (CI &amp;lt; 1). The combination of olaparib and vincristine trended toward antagonism (CI &amp;gt; 1). Conclusions: The addition of olaparib to DNA damaging agents resulted in additive or synergistic growth inhibition in a panel of pediatric solid tumor cell lines. Further preclinical and clinical evaluation to determine if olaparib can enhance the efficacy of current pediatric chemotherapy regimens is warranted. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 5357. doi:10.1158/1538-7445.AM2011-5357
OC-058 Ambulatory Care Alcohol Detoxification (acad) At Whittington Health: A New Approach !
Authors: VSS Wong, R Turner, J Pleming
Journal: Gut (2014)

<h3>Introduction</h3> Alcohol-related harm costs NHS £3.5 billion a year. It has become a “top priority” for the NHS. Alcohol Concern reported 1.2 million alcohol-related admissions in 2011/12, an increase of 135% over the last 10 years, but more people are also seeking and completing treatment. Current standard treatment for those actively withdrawing from alcohol is for inpatient (IP) detoxification and concurrent assessment and intervention by an Alcohol Liaison Nurse (ALN) which usually takes, on average, 5–7 days as an IP. <h3>Methods</h3> A care pathway was formulated for inpatients to be referred to the AC service based on strict guideline. The AC centre dedicated 2 appointments daily within working hours (Mon-Fri) for outpatient (OP) detoxification. During each session, the ALN assessed, breathalysed the patient and completed a Clinical Institute Withdrawal Scale (CIWA). The AC doctor then prescribed a daily regimen of chlordiazepoxide on a symptom-dose basis. A retrospective audit was completed of all patients referred through this pathway. <h3>Results</h3> From Jan 13-Dec 13, 19 patients (after medically assessed) were referred for the ACAD after 3 days. 14 patients engaged with the service and completed their AD. 10 male, 4 female, aged 28–68 years. All patients were admitted via Emergency Dept; 8 presented with alcohol withdrawal, 6 with other acute problems but concurrently treated for alcohol withdrawal whilst IP. 10 had physical co-morbidities; 2 had psychiatric co-morbidities. 6 patients had a previous history of seizures. 2/14 patients consumed alcohol during the AD phase of their treatment (noted on breathalysing the patients). These patients were subsequently discharged from ambulatory care and referred to local alcohol services. 1 patient required readmission to hospital for physical concerns relating to diabetes, completing the remainder of the detoxification as an IP. All patients agreed to be followed up in the community and have engaged with community services. The average duration of AD was 5 days. In previous study we have estimated that a 7 day inpatient admission as costing £2183 vs a 3 day admission with 3 follow up ambulatory appointments costing £1352. The potential cost saving is significant once this service is widely used. <h3>Conclusion</h3> This small innovative pilot study demonstrates that ACAD can be an effective and safe approach to the managing acute alcohol withdrawal; enable continued monitoring of vulnerable patients in a controlled OP environment. There is a need for a paradigm shift of offering AD in AC setting rather than IP treatment. Further patients are beibng recruited into an ongoing study. <h3>References</h3> Public Health England, Alcohol Treatment in England 2012-13 Alcohol Concern, www.alcoholconcern.org Barry <i>et al</i>., Alcohol Inpatient Detox: Withdrawing the burden of inpatient management. Gut, 2013 <h3>Disclosure of Interest</h3> None Declared.
Clinical and immunological features and outcome of anti-p200 pemphigoid
Authors: M.-H. Commin, E. Schmidt, S. Duvert-Lehembre, A. Lasek, C. Morice, J.-L. Estival, S. Debarbieux, E. Rigal, C. Pauwels, J. De Quatrebarbes, A. Roussel, E. Goujon, P.-E. Stoebner, F. Jouen, P. Joly
Journal: British Journal of Dermatology (2016)

Anti‐p200 pemphigoid is a rare autoimmune blistering disease (AIBD) of the dermoepidermal junction, characterized by autoantibodies to laminin γ1. The clinical course of anti‐p200 pemphigoid in patients remains poorly investigated. We aimed to describe the clinical and immunological features and the course of a series of patients with anti‐p200 pemphigoid. We conducted a retrospective study by immunoblotting detection of sera on 200‐kDa dermal protein extracts from the register of the French reference centre for AIBD. We recorded the clinical and immunological features and the course of patients. A total of 14 patients with a mean age 81·6 ± 6·5 years were included. Only one patient had an associated neurological condition and one had psoriasis. Twelve patients had atypical clinical presentation, including eczematous, urticarial, prurigo‐like, dyshydrosis‐like and rosette‐like skin lesions. Eight patients (57%) had mucosal involvement. Immunoblot analysis of sera on dermal and epidermal extracts showed a 200‐kDa band in 14 and 10 cases, respectively. All eight of the sera tested by enzyme‐linked immunosorbent assay detected recombinant human laminin γ1. Disease control was obtained in six of nine patients treated with topical corticosteroids, and four of five patients who received systemic treatment. Seven patients relapsed (50%) and five patients (36%) died during the median follow‐up time of 12·6 months. At the end of the study, only one of the nine living patients was in complete remission off therapy. Many patients with anti‐p200 pemphigoid had heterogeneous clinical presentation and a more severe prognosis than previously suspected.